World Journal of
Pharmaceutical and Life Sciences

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Life Sciences
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
World Journal of Pharmaceutical and Life Sciences (WJPLS) has indexed with various reputed international bodies like : Google Scholar, Index Copernicus, Indian Science Publications, SOCOLAR, China, Cosmos Impact Factor, Research Bible, Fuchu, Tokyo. JAPAN, Scientific Indexing Services (SIS), Jour Informatics (Under Process), UDLedge Science Citation Index, Global Impact Factor (In Process), International Impact Factor Services, International Scientific Indexing, UAE, International Society for Research Activity (ISRA) Journal Impact Factor (JIF), Science Library Index, Dubai, United Arab Emirates, International Innovative Journal Impact Factor (IIJIF), Scientific Journal Impact Factor (SJIF), Eurasian Scientific Journal Index (ESJI), Indian citation Index (ICI), IFSIJ Measure of Journal Quality, International Scientific Indexing, UAE (ISI), Web of Science Group (Under Process), Directory of Research Journals Indexing, 



Indrani Chakraborty, Rafi Ahammed Reja, Sougata Karmakar and Dr. Nirmal Pradhan*


The existence of Chromium(Cr) was discovered by Vauquelin in 1797 and its physical and chemical properties have sequentially been determined afterwards. Most of the studies on health effects involve exposure to chromium 0, II?, IV and chromium-VI compounds. Cr-VI in the environment is almost always related to anthropogenic activity. The most common form of Cr-VI is readily solubilised from most soil and transported through water that contacts the soils and used for industrial and commercial productions which have become more prevalent environmental contaminants. Accidental or intentional ingestion of extremely high doses of Cr-VI compounds has resulted in severe respiratory, cardiovascular, gastrointestinal, hematological, hepatic, renal and neurological effects in man as a part of the sequelae leading to death or in patients who survived because of medical treatment. But no reports are available on chronic oral exposure of Cr-VI at equivalant to human RDA doses on hematological parameters in rats as the mammalian model. In the present study, Cr-VI has been administered orally through gavage to adult male albino rats at the doses of 1mg, 1.5mg and 2mg /100gm body weight/day, accordingly to Gr. 1, 2 and 3 for consicutive 33 days with water ad libitum. The results showed no significant changes in body weight gain, Haemoglobin level, blood glucose level, serum protein, serum alkaline phosphatase activity and SGPT activity. Only the mild increased activity was found in SGOT in group-3. So, it can be surmised that, Cr-VI has no such potent toxic effects in this treated doses and duration on male rats as the mammalian system.

[Full Text Article]


World Journal of Pharmaceutical and life sciences Will give best paper award in every issue in the from of money along with certificate to promote research .

Best Article of current issue

Download Article : Click here